NasdaqCM - Nasdaq Real Time Price USD

MetaVia Inc. (MTVA)

0.6670

+0.0170

+(2.62%)

At close: May 14 at 4:00:01 PM EDT

MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the first quarter ended March 31, 2025, and provided a corporate strategic update.

PR Newswire 14 hours ago

MTVA
+2.62%
MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

MetaVia Inc. (Nasdaq: MTVA) ("MetaVia"), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a private placement that MetaVia estimates will result in gross proceeds of approximately $10.0 million, before deducting the placement agent's fees and other offering expenses payable by the company. MetaVia currently intends to use the net proceeds from the offering for working capital and corporate purposes, including to continue the clinical develo

PR Newswire 5 days ago

MTVA
+2.62%
MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that data from its Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH), demonstrates both hepatoprotective and glucose-regulating effects. The data will be presented in late-breaking poster presentation at the European Association for the Stud

PR Newswire 8 days ago

MTVA
+2.62%
MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting data from its Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH), has been accepted as a late-breaking poster presentation at the European Association for the Study of the Liver (EASL) Congress 2025, taking place

PR Newswire 21 days ago

MTVA
+2.62%
MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today reported additional top-line results from the multiple ascending dose (MAD) Part 2 of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), further demonstrating its potential as a best-in-class obesity drug.

PR Newswire 22 days ago

MTVA
+2.62%
MTVA: Positive Phase 1 MAD Data for DA-1726; Excellent Tolerability Profile and Mean Day 26 Weight Loss of 4.3%…

By David Bautz, PhD NASDAQ:MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Positive Phase 1 MAD Data for DA-1726 On April 15, 2025, MetaVia Inc. (NASDAQ:MTVA) announced positive results from the Phase 1 Part 2 multiple ascending dose (MAD) trial of DA-1726 in obesity. The results showed that the cohort receiving 32 mg of DA-1726 with no titration had a maximum reduction in body weight

Zacks Small Cap Research 29 days ago

MTVA
+2.62%
MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced positive results from the 4-week multiple ascending dose (MAD) Part 2 of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity.

PR Newswire 29 days ago

MTVA
+2.62%
MTVA: Phase 1 Part 2 Data for DA-1726 in Obesity Expected Soon…

By David Bautz, PhD NASDAQ:MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Data Expected in April 2025 from Part 2 of Phase 1 Trial of DA-1726 MetaVia Inc. (NASDAQ:MTVA) is currently conducting a Phase 1 clinical trial of DA-1726 in patients with obesity. In September 2024, MetaVia announced positive topline results for the single ascending dose (SAD) Part 1 of the trial. A total of 45

Zacks Small Cap Research last month

MTVA
+2.62%

ABBV
MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the year ended December 31, 2024 and provided a corporate strategic update.

PR Newswire last month

MTVA
+2.62%
Zacks Small Cap Research 2024 Initiations and Best Ideas for 2025

Zacks Small Cap Research was hard at work in 2024 initiating analyst coverage on 40 companies. Each of our initiation reports provides a valuation, investment thesis and financial forecast model that comes from our 11 experienced analysts’ expertise and due diligence. Our work has generated investment ideas in health care, consumer electronics, finance technologies, transportation, AI-based

Zacks Small Cap Research 3 months ago

MTVA
+2.62%

LGNZZ

TELO
MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it is holding an Advisory Committee meeting today, at the 9th Annual MASH-TAG 2025 Conference, to discuss the previously announced positive top-line 16-week results from the two-part Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH). Th

PR Newswire 4 months ago

MTVA
+2.62%
MTVA: Compelling Data for DA-1241 in Phase 2a MASH Trial…

By David Bautz, PhD NASDAQ:MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Compelling Results for DA-1241 in Phase 2a MASH Trial On December 18, 2024, MetaVia Inc. (NASDAQ:MTVA) announced positive topline results from the 16-week Phase 2a clinical trial of DA-1241 in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH). The trial had two parts: in Part 1,

Zacks Small Cap Research 4 months ago

MTVA
+2.62%
MetaVia to Participate in the 9th Annual MASH-TAG 2025 Conference After Releasing Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it will participate as a Sponsor and Exhibitor at the upcoming, 9th Annual MASH-TAG 2025 Conference. The company's participation follows the recent release of positive top-line 16-week results from the two-part Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, in patients with presumed metabolic dysfunction-associate

PR Newswire 4 months ago

MTVA
+2.62%
MetaVia Announces Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced positive top-line 16-week results from the two-part Phase 2a clinical trial in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH). Part 1 of this Phase 2a trial is exploring DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist compared to placebo, while Part 2 is investigating the efficacy of DA-1241 in combination with sita

PR Newswire 4 months ago

MTVA
+2.62%
Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing

Investor Summit Group, committed to advancing the MicroCap and SmallCap investment community, announces that the November 21, 2024 Winter Investor Summit Virtual Conference presentations are now available for on-demand viewing. Participants and those ...

ACCESS Newswire 5 months ago

LMFA

CPSH

PLUR
Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now

MIAMI, Dec. 03, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 77th Emerging Growth Conference on December 4 & 5, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting compa

GlobeNewswire 5 months ago

BNRG

ICON

VIOT
MTVA: NeuroBo Becomes MetaVia; Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024…

By David Bautz, PhD NASDAQ:MTVA READ THE FULL MTVA RESEARCH REPORT Business Update NeuroBo Becomes MetaVia On November 18, 2024, NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) announced a strategic realignment ahead of upcoming clinical milestones along with a corporate name change to MetaVia Inc. (NASDAQ:MTVA). The change went into effect on November 29, 2024. We are republishing the latest

Zacks Small Cap Research 5 months ago

MTVA
+2.62%
MetaVia to Present at the Emerging Growth Conference in December

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H. Woodworth, Chief Financial Officer, will present a company update at the Emerging Growth Conference on Wednesday, December 4, 2024 at 4:10 pm ET.

PR Newswire 5 months ago

MTVA
+2.62%

Performance Overview

Return	MTVA	S&P 500 (^GSPC)
YTD	-67.14%	+0.19%
1-Year	-83.77%	+12.31%
3-Year	-99.45%	+46.44%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

MetaVia Inc. (MTVA)

MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update

MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025

MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025

MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential

MTVA: Positive Phase 1 MAD Data for DA-1726; Excellent Tolerability Profile and Mean Day 26 Weight Loss of 4.3%…

MTVA: Phase 1 Part 2 Data for DA-1726 in Obesity Expected Soon…

MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update

Zacks Small Cap Research 2024 Initiations and Best Ideas for 2025

MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference

MTVA: Compelling Data for DA-1241 in Phase 2a MASH Trial…

MetaVia to Participate in the 9th Annual MASH-TAG 2025 Conference After Releasing Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH

MetaVia Announces Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH

Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing

Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now

MTVA: NeuroBo Becomes MetaVia; Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024…

MetaVia to Present at the Emerging Growth Conference in December

Performance Overview